ACE-CL-001, ASCEND trials demonstrate long-term efficacy and tolerability of Calquence in CLL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In the ACE-CL-001 trial, data showed 97% of previously untreated CLL patients continued to respond to treatment after more than four years with no new safety signals.

In the pivotal ASCEND trial, an estimated 82% of CLL patients with relapsed or refractory disease treated with Calquence remained progression free at 18 months vs. 48% for comparators. Overall, Calquence data delivered meaningful long-term clinical benefit with a favorable safety profile for patients with CLL, regardless of whether they’re new to treatment or are managing relapsed or refractory disease.

A link to the ACE-CL-001 trial abstract can be found here, and the ASCEND trial abstract here.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login